While it is not completely specific, examination for the MYD88 L265P mutation is routine in clinical practice because the immunophenotype of LPL can overlap other B-cell lymphomas that lack expression of CD5 and CD10 [21]. This evidence concerns the gene LPL and B-cell non-Hodgkin lymphoma.